New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Mark Cuban: A Master Disrupter for American Health...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
High-speed imaging tracks live brain cell activity...
World is falling behind on UN's child mortality Sustainable ...
April 16,2026
Health literacy initiative improves discharge education, rea...
April 15,2026
Constipation is common, but with simple changes, you can man...
April 14,2026
Children and teenagers more open to meat free diets—but stru...
April 13,2026
3D-printed ATLAS platform helps model cancer cell clusters b...
April 12,2026
3 million-cell map shows menopause reshapes breast tissue, p...
April 11,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Today's News
Why is Alzheimer’s disease so difficult to treat? ...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Novel therapy studied for inherited breast cancer

Novel therapy studied for inherited breast cancer

by Will Sansom,University of Texas Health Science Center at San AntonioCredit: CC0 Public DomainUT Health San Antonio researchers have discovered a novel way to kill cancers that are caused by a
Oncology May 27,2024
Novel therapy studied for inherited breast cancer

Novel therapy studied for inherited breast cancer

by Will Sansom,University of Texas Health Science Center at San AntonioCredit: CC0 Public DomainUT Health San Antonio researchers have discovered a novel way to kill cancers that are caused by a
Oncology May 27,2024
Team identifies protein key to cancer cells ability to spread

Team identifies protein key to cancer cells ability to spread

by University of GuelphProfessor Jim Uniacke in his specialized lab. Credit: Rob O'FlanaganUniversity of Guelph scientists have made a discovery that could reduce the spread of cancer by hind
Oncology May 27,2024
Team identifies protein key to cancer cells ability to spread

Team identifies protein key to cancer cells ability to spread

by University of GuelphProfessor Jim Uniacke in his specialized lab. Credit: Rob O'FlanaganUniversity of Guelph scientists have made a discovery that could reduce the spread of cancer by hind
Oncology May 27,2024
Team finds key to common cancer pathway

Team finds key to common cancer pathway

by Terry Devitt,University of Wisconsin-MadisonThe molecular pathway for the protein p53, commonly associated with many cancers, is illuminated in this micrograph. The p53 - PIP2 complex is show
Oncology May 27,2024
Team finds key to common cancer pathway

Team finds key to common cancer pathway

by Terry Devitt,University of Wisconsin-MadisonThe molecular pathway for the protein p53, commonly associated with many cancers, is illuminated in this micrograph. The p53 - PIP2 complex is show
Oncology May 27,2024
Team develops test to predict immunotherapy response in kidney cancer

Team develops test to predict immunotherapy response in kidney cancer

by UT Southwestern Medical CenterLeft, illuminated tumor by iPET expressing immunotherapy target, compared to control tumor (right). Credit: UTSWA novel imaging test shows promise for identifying
Oncology May 27,2024
Team develops test to predict immunotherapy response in kidney cancer

Team develops test to predict immunotherapy response in kidney cancer

by UT Southwestern Medical CenterLeft, illuminated tumor by iPET expressing immunotherapy target, compared to control tumor (right). Credit: UTSWA novel imaging test shows promise for identifying
Oncology May 27,2024
Study confirms protein as potential cause of most common type of pancreatic cancer

Study confirms protein as potential cause of most common type of pancreatic cancer

by University of Texas M. D. Anderson Cancer CenterAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainResearchers at The University of Texa
Oncology May 27,2024
Study confirms protein as potential cause of most common type of pancreatic cancer

Study confirms protein as potential cause of most common type of pancreatic cancer

by University of Texas M. D. Anderson Cancer CenterAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainResearchers at The University of Texa
Oncology May 27,2024
Study confirms effectiveness of newer arthritis meds

Study confirms effectiveness of newer arthritis meds

by Amy NortonNewer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study.The study, of 622 adul
Oncology May 27,2024
Study confirms effectiveness of newer arthritis meds

Study confirms effectiveness of newer arthritis meds

by Amy NortonNewer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study.The study, of 622 adul
Oncology May 27,2024
Team explores anti-breast cancer properties of soy

Team explores anti-breast cancer properties of soy

by University of ArizonaOrnella I. Selmin, PhD (left), and Donato F. Romagnolo, PhD (right). Credit: University of Arizona Cancer CenterA University of Arizona Cancer Center research team is enga
Oncology May 27,2024
Team explores anti-breast cancer properties of soy

Team explores anti-breast cancer properties of soy

by University of ArizonaOrnella I. Selmin, PhD (left), and Donato F. Romagnolo, PhD (right). Credit: University of Arizona Cancer CenterA University of Arizona Cancer Center research team is enga
Oncology May 27,2024
Team targets tumor suppressor to treat 'triple-negative' breast cancer

Team targets tumor suppressor to treat 'triple-negative' breast cancer

by University of Arizona Health SciencesAgnieszka Witkiewicz, MD and Erik Knudsen, PhD, UA Cancer Center. Credit: BioCommunications, Kris HanningA study by scientists at the University of Arizona Canc
Oncology May 27,2024
Team targets tumor suppressor to treat 'triple-negative' breast cancer

Team targets tumor suppressor to treat 'triple-negative' breast cancer

by University of Arizona Health SciencesAgnieszka Witkiewicz, MD and Erik Knudsen, PhD, UA Cancer Center. Credit: BioCommunications, Kris HanningA study by scientists at the University of Arizona Canc
Oncology May 27,2024
Onions and garlic may be recipe for reducing breast cancer risk: study

Onions and garlic may be recipe for reducing breast cancer risk: study

by David J. Hill,University at BuffaloCredit: CC0 Public DomainOnions and garlic are key ingredients in sofrito, a condiment that's a staple of Puerto Rican cuisine. They may also be a recip
Oncology May 27,2024
Onions and garlic may be recipe for reducing breast cancer risk: study

Onions and garlic may be recipe for reducing breast cancer risk: study

by David J. Hill,University at BuffaloCredit: CC0 Public DomainOnions and garlic are key ingredients in sofrito, a condiment that's a staple of Puerto Rican cuisine. They may also be a recip
Oncology May 27,2024
Significant proportion of cancer drugs lack proof of added benefit, finds study

Significant proportion of cancer drugs lack proof of added benefit, finds study

by British Medical JournalCredit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved
Oncology May 26,2024
Significant proportion of cancer drugs lack proof of added benefit, finds study

Significant proportion of cancer drugs lack proof of added benefit, finds study

by British Medical JournalCredit: CC0 Public DomainMany cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved
Oncology May 26,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu... ... Eye Infections (Updated) | Clinical Medicine ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com